Completed PHASE4 INTERVENTIONAL 2-arm NCT05049447

Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety

Proof of Effectiveness of Pascoflair Using Qantitative Measurement of Electric Brain Activity During Examination Stress in 40 Subjects Suffering From Test Anxiety. A Double-blind, Randomized, Placebo-controlled, 2-armed, Phase IV Study in Parallel Design.

Sponsor: NeuroCode AG

Conditions Brain Activity Passiflora Incarnata Stress Test Anxiety

Interventions Pascoflair Placebo

Updated 3 times since 2021 Last updated: Sep 16, 2021 Started: May 31, 2015 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Brain Activity and Passiflora Incarnata and is currently completed. NeuroCode AG leads this study, which shows 3 recorded versions since 2015 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Oct 2021 — Jul 2024 [monthly]

Completed PHASE4

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NeuroCode AG
Pascoe Pharmazeutische Praeparate GmbH

Data source: Pascoe Pharmazeutische Praeparate GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.